Article citationsMore>>

De Champs, C., Monne, C., Bonnet, R., Sougakoff, W., Sirot, D., Chanal, C., et al. (2001) New TEM Variant (TEM-92) Produced by Proteus mirabilis and Providencia Stuartii Isolates. Antimicrobial Agents and Chemotherapy, 45, 1278-1280. http://dx.doi.org/10.1128/AAC.45.4.1278-1280.2001

has been cited by the following article:

• TITLE: Antimicrobial Resistance and Genotype Analysis of Extended-Spectrum-β-Lactamase-Producing Proteus Mirabilis

  AUTHORS: Ying Huang, Yuanhong Xu, Zhongxin Wang, Xianghong Lin

  KEYWORDS: Genotype; Extended-Spectrum-β-Lactamase; Antimicrobial Resistance; Proteus Mirabilis

  JOURNAL NAME: Open Journal of Clinical Diagnostics, Vol.4 No.1, March 21, 2014

  ABSTRACT: To analyse the genotypes of clinical isolates of Extended-Spectrum-β-Lactamase-Producing (ESBL-producing) Proteus mirabilis (P. mirabilis) and the mechanisms of antimicrobial resistance, to guide reasonable use of antibiotics and to avoid nosocomial outbreak infections by ESBL-producing P. mirabilis. 125 clinical isolates of P. mirabilis were collected from the Drug-Resistant Bacteria Surveillance Center of Anhui Province (from Jan 2009 to May 2010). Searching for the genotypes of ESBLs was perfomed by PCR amplification and DNA sequencing, and performed conjugation test simultaneously. Among ESBL-producing strains, CTX-M was the major genotype (3 CTX-M-13 and 1 CTX-M-3). TEM-1b spectrum β-lactamase was also prevalence in P. mirabilis. The diversity of β-lactamases in P. mirabilis and the emergency of multi-drug-resistance clinical strains will present serious threat to clinical therapy and even will lead to outbreak of nosocomial infections. Our study emphasizes the need for enhanced supervision of ESBL-producing P. mirabilis. Timely and reasonable drug-resistance data are indispensable to clinical therapy.